The medications — a CXCR4 antagonist used for bone marrow transplants and a beta-3 adrenergic agonist for bladder control — could be used to repair bone fractures of the spine, hip and leg post-surgery.
Researchers triggered the bone marrow of healthy rats to release mesenchymal stem cells and aid in the healing of fractures.
The study is led by scientists from Imperial College London in England, and includes researchers from Southfield, Mich.-based Beaumont Health.
More articles on biologics:
Stryker ranks No. 8 in Fortune’s 100 best workplaces
Wuhan neurosurgeon, hospital director dies from coronavirus, death toll rises to 1,800+
Medtronic reports spine revenue up 3%, hurt by low BMP sales: 7 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
